New drugs for rheumatological conditions may be missing out on PBS listings because the rheumatology speciality is not providing the right input to the Pharmaceutical Benefits Advisory Committee, the chair of the committee says. PBAC chair Professor Andrew Wilson told the ARA 2018 conference in Melbourne that rheumatologists could learn a lot from oncologists when ...
PBS chief wants better advice from rheumatologists on new listings
By Michael Woodhead
10 May 2018